Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.62 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305783 | 0.86 | MEN1 (0.66) | CSNK2A2CSNK2BCSNK2A1MAPTSMN1; SMN2 | |
| SCHEMBL5309179 | 0.83 | TERT (0.73) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL311865 | 0.83 | TERT (0.68) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL23299598 | 0.82 | ESR1 (0.68) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL13355967 | 0.81 | CYP1A1 (0.70) | CSNK2A2CSNK2BCSNK2A1MAPTCYP3A4 | |
| SCHEMBL312870 | 0.80 | TERT (0.61) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL4649959 | 0.79 | TERT (1.00) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL31322174 | 0.79 | TERT (1.00) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL24046928 | 0.77 | CSNK2A2 (0.65) | TERTCSNK2A2CSNK2BCSNK2A1MAPT | |
| SCHEMBL15231415 | 0.77 | CSNK2A2 (0.65) | TERTCSNK2A2CSNK2BCSNK2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000121-A1 | APIGENIN GLYCOSIDES FLAVOR ENHANCERS | OHIO STATE INNOVATION FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-8293315-B2 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293315-B2 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-1738738-B1 | Microcapsules | COGNIS IP MAN GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2060251-B1 | Method for manufacturing active agent concentrates | COGNIS IP MAN GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100009063-A1 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100009063-A1 | Process for the preparation of active substance concentrate | COGNIS IP MANAGEMENT GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2060251-A1 | Method for manufacturing active agent concentrates | Cognis IP Management GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| EP-1623757-B1 | Microcapsules (XXXII) | COGNIS IP MAN GMBH (DE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | COGNIS IP MANAGEMENT GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | COGNIS IP MANAGEMENT GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | COGNIS IP MANAGEMENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | COGNIS IP MANAGEMENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1967197-A1 | Use of preparations, purifications and extracts of aloe | Cognis IP Management GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008046521-A1 | PREPARATION FOR ORAL ADMINISTRATION (II) | COGNIS IP MANAGEMENT GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008028585-A2 | COSMETIC AND/OR PHARMACEUTICAL PREPARATIONS CONTAINING HOODIA EXTRACTS | COGNIS IP MANAGEMENT GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028584-A1 | PREPARATIONS FOR ORAL ADMINISTRATION (I) | COGNIS IP MANAGEMENT GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007068390-A1 | PRE-MIXES FOR PERSONAL AND HOME CARE COMPOSITIONS | COGNIS IP MANAGEMENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| EP-1798279-A1 | Pre-mixes for personal and home care compositions | Cognis IP Management GmbH (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1738738-A1 | Microcapsules | Cognis IP Management GmbH (DE) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268024-A1 | Compositions for Oral and/or Topical Administration | FABP2, FABP6, CUTA | TERT 2054/4885CSNK2A2 4555/4885CSNK2B 4617/4885 |
| US-20080220101-A1 | COMPOSITIONS OF EXTRACTS OF ALOE FOR ORAL ADMINISTRATION | LIPE, ALOX15, ALOX5 | TERT 4301/4885CSNK2A2 1678/4885CSNK2B 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.